SNDX - CIK 0001395937
Syndax Pharmaceuticals Inc trades as SNDX and has a market capitalization of $1.56 B, making it the #2297 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $172.35M, up 627.8% from the prior year and net income of -$285.40M. This page tracks Syndax Pharmaceuticals Inc through 636 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Syndax Pharmaceuticals Inc's revenue grew from $1.22M to $172.35M, a compound annual growth rate of 73.3%. Net profit margin expanded from -3645.2% to -165.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G/A | - | 2026-03-27 |
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who
The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026 , at 9:20 a.m. ET .
The largest companies sharing Syndax Pharmaceuticals Inc's SEC industry classification (pharmaceutical preparations).
Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $1.56 B as of 2026-06-10, ranking #2297 among US-listed companies.
Syndax Pharmaceuticals Inc reported revenue of $172.35M for fiscal year 2025, an increase of 627.8% year over year.
In its latest fiscal year Syndax Pharmaceuticals Inc reported a net loss of $285.40M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition